Off-label Use of Ceftazidime/Avibactam in Neonatal Intensive Care Unit: A Real-life Experience and Literature Review.
Argyro FtergiotiMelania Degli AntoniAngeliki KontouMaria KourtiKalliopi PantzartziCharalampos ZarrasEleni AgakidouKosmas SarafidisEmmanuel RoilidesElias IosifidisPublished in: The Pediatric infectious disease journal (2024)
Favorable clinical and microbiological responses in neonatal intensive care unit patients treated with CZA off-label were observed without significant and unexpected adverse events in critically ill neonates.